Where do investigators go next with the 8000-plus COPD patient research?
The newest phase 3 findings of the Efficacy and Safety of Triple Therapy in Obstructive Lung Disease (ETHOS) trial showed triple therapy inhaler budesonide/glycopyrrate/formoterol significantly reduced exacerbations, mortality risk, and burdened quality-of-life metrics among patients with chronic obstructive pulmonary disease (COPD).
The findings, which were presently virtually at the American Thoracic Society (ATS) 2020 Virtual Sessions this week by investigator Klaus F. Rabe, MD, featured 8000-plus patients treated with either dual- or triple-therapy inhaler for their COPD. Aside from showing the value of a burgeoning field of care, the ETHOS trial provided a gold mine of COPD patient data.
In the final part of an interview with HCPLive®, Rabe, of the Airway Research Center North in Germany, discussed the benefit of having enough pooled patient analyses to further assess in understanding COPD care and pathophysiology.
“There’s a lot of analyses that are to be done which are not part of the core paper,” Rabe said. “There will be a separate, real workup on mortality—very interesting data—and it’s clearly a workup we have to do.”
Rabe also discussed plans to use this supplemental data to interpret risk-benefit ratios as they pertain to triple therapy COPD—and how such findings may influence clinical guidelines.
Related Content:American Thoracic Society International Conference | Conference | Pulmonology | COPD